Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Omeros Corporation (NASDAQ:OMER) has received an average recommendation of "Moderate Buy" from six brokerages, including a mix of buy and hold ratings.
• The average one-year price target set by analysts for Omeros is $18.00, with varying targets from $9.00 to $36.00.
• Omeros reported a quarterly earnings per share (EPS) of ($0.53), exceeding analyst expectations, alongside a revenue of $28.60 million for the quarter.

Omeros Corporation (NASDAQ:OMER - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $18.00.

OMER has been the topic of a number of research analyst reports. D. Boral Capital reissued a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Wednesday, September 3rd. HC Wainwright reissued a "buy" rating and set a $9.00 price objective on shares of Omeros in a research report on Friday, June 27th. Wall Street Zen raised shares of Omeros from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Friday, August 15th.

Omeros Stock Performance

Shares of OMER opened at $4.28 on Wednesday. The firm has a market cap of $291.30 million, a price-to-earnings ratio of -2.03 and a beta of 2.37. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The firm has a 50 day moving average price of $4.07 and a 200-day moving average price of $4.93.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.02. The company had revenue of $28.60 million for the quarter, compared to analysts' expectations of $0.31 million. As a group, equities research analysts predict that Omeros will post -3.09 earnings per share for the current year.

Institutional Trading of Omeros

A number of hedge funds and other institutional investors have recently modified their holdings of OMER. Ameriprise Financial Inc. grew its position in shares of Omeros by 2.0% in the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock worth $1,190,000 after buying an additional 2,317 shares during the period. Deutsche Bank AG grew its position in shares of Omeros by 38.2% in the 4th quarter. Deutsche Bank AG now owns 40,046 shares of the biopharmaceutical company's stock worth $396,000 after buying an additional 11,068 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Omeros by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock worth $314,000 after buying an additional 1,110 shares during the period. Millennium Management LLC grew its position in shares of Omeros by 46.2% in the 4th quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company's stock worth $846,000 after buying an additional 27,088 shares during the period. Finally, ProShare Advisors LLC grew its position in shares of Omeros by 75.0% in the 4th quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company's stock worth $183,000 after buying an additional 7,927 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.